灌注米托蒽醌预防膀胱癌术后复发的临床观察

Clinical study of intravesical perfusion Mitoxantrone for the prevention of postoperation recurrence of bladder cancer

目的探讨膀胱灌注米托蒽醌(MTZ)预防膀胱癌术后复发的疗效及安全性.方法对116例浅表性膀胱癌患者行TURBT或膀胱部分切除术,术后1周用MTZ 10 mg进行膀胱内定期灌注,并随访5～72月.结果 116例患者均未见全身性药物不良反应,仅7例出现轻微膀胱刺激症状;复发12例,复发率10.34%.结论膀胱灌注MTZ预防膀胱癌术后复发的疗效确切,不良反应少,安全性好.

OBJECTIVE To evaluate the effect and safety of intravesical perfusion of Mitoxantrone（ MTZ）for the prevention of postoperative recurrence of bladder cancer. METHODS 116 patients underwent TURBT or partial cystectomy of the bladder cancer. Intravesical perfusion of 10 mg MTZ, dissolved in 40 ml normal saline and retained in bladder for 1 - 2 hours was given to bladder cancer patients postoperatively once a week for 8 weeks and subsequently once a month for 10 months. RESULTS All of the 116 cases were followed up for 5 - 72 months. Tumor reeurrence occurred in 12 cases, with recurrence rate of 10.34%. There was no generalized side effect. Minor bladder irritation was noted only in 7 cases. CONCLUSION Intravesical perfusion of MTZ is effective for the prevention of postoperative recurrence of superficial bladder cancer, with safety and less side effect.